drugset / Trial / NCT06336356

A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension

NCT06336356

Phase 2 Completed 48 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to assess the serum free cortisol response after ACTH stimulation test at baseline and at Week 8 in participants with uncontrolled hypertension.

Timeline

Start
2024-06-10
Primary completion
2024-12-04
Completion
2024-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Baxdrostat Small molecule 2 mg Oral

Indications